Literature DB >> 27362691

The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.

Magali de Bruyn1,2, Jennifer Vandooren1, Estefania Ugarte-Berzal1, Ingrid Arijs2,3, Séverine Vermeire2,4, Ghislain Opdenakker1.   

Abstract

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are thought to be predominant proteases and protease inhibitors involved in the pathogenesis of inflammatory bowel diseases (IBD) through their ability to remodel the extracellular matrix (ECM) in response to inflammatory stimuli and by their immunomodulating effects. An imbalance between MMPs and TIMPs has been linked with acute and chronic inflammation and aberrant tissue remodeling, as seen in IBD. Moreover, recurrent phases of tissue destruction and subsequent tissue repair can cause serious complications in IBD patients such as fistulas and fibrosis. The aims of this review are (i) to summarize current literature on genetic association, mRNA, and protein expression studies with regard to MMPs and TIMPs in IBD patients and various animal models, including those with transgenic and knockout mice; (ii) to compare biochemical and molecular biological data in humans with those obtained in animal model studies and (iii) to critically evaluate and translate how this knowledge may be used in practical terms to understand better the pathophysiology and mechanisms operating in IBD and to apply this for improvement of clinical outcomes at diagnostic, prognostic and therapeutic levels.

Entities:  

Keywords:  Adaptive immunity; IBD; MMP; TIMP; association studies; autoimmunity; degradome; inflammation; innate immune defense; interaction; network hypothesis; neutrophils; protease web; remnant epitopes

Mesh:

Substances:

Year:  2016        PMID: 27362691     DOI: 10.1080/10409238.2016.1199535

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  25 in total

Review 1.  Intestinal fibrosis: ready to be reversed.

Authors:  Giovanni Latella; Florian Rieder
Journal:  Curr Opin Gastroenterol       Date:  2017-07       Impact factor: 3.287

Review 2.  Redox Imbalance in Intestinal Fibrosis: Beware of the TGFβ-1, ROS, and Nrf2 Connection.

Authors:  Giovanni Latella
Journal:  Dig Dis Sci       Date:  2018-02       Impact factor: 3.199

Review 3.  Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

Review 4.  Matrix metalloproteinases and inhibitors in dentistry.

Authors:  Gerd-Jan Boelen; Lucas Boute; Joëy d'Hoop; Mostafa EzEldeen; Ivo Lambrichts; Ghislain Opdenakker
Journal:  Clin Oral Investig       Date:  2019-05-15       Impact factor: 3.573

Review 5.  Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface.

Authors:  Vassilis Valatas; Eirini Filidou; Ioannis Drygiannakis; George Kolios
Journal:  Ann Gastroenterol       Date:  2017-04-12

6.  Mycobacterium avium lysate induces matrix metalloproteinase-1 in intestinal tissue and peripheral blood: Observations from selected hospital based Zambian adults.

Authors:  Gershom Chongwe; Charles Michelo; Edford Sinkala; Violet Kayamba; Jean-Baptiste Nzayisenga; Francis Drobniewski; Paul Kelly
Journal:  Int J Infect Dis       Date:  2018-04-20       Impact factor: 3.623

7.  Expression profile of matrix metalloproteinases in the labrum of femoroacetabular impingement.

Authors:  Jason Schon; Jorge Chahla; Sharada Paudel; Lumanti Manandhar; Tyler Feltham; Johnny Huard; Marc Philippon; Zijun Zhang
Journal:  Bone Joint Res       Date:  2020-05-16       Impact factor: 5.853

Review 8.  Monoclonal antibodies against metzincin targets.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

9.  Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease.

Authors:  Magali de Bruyn; Christine Breynaert; Ingrid Arijs; Gert De Hertogh; Karel Geboes; Greet Thijs; Gianluca Matteoli; Jialiang Hu; Jo Van Damme; Bernd Arnold; Marc Ferrante; Séverine Vermeire; Gert Van Assche; Ghislain Opdenakker
Journal:  Nat Commun       Date:  2017-05-31       Impact factor: 14.919

10.  Gelatinase B/Matrix Metalloproteinase-9 as Innate Immune Effector Molecule in Achalasia.

Authors:  Janette Furuzawa-Carballeda; Lise Boon; Gonzalo Torres-Villalobos; Fernanda Romero-Hernández; Estefania Ugarte-Berzal; Erik Martens; Jennifer Vandooren; Vasily Rybakin; Enrique Coss-Adame; Miguel Valdovinos; David Velazquez-Fernández; Ghislain Opdenakker
Journal:  Clin Transl Gastroenterol       Date:  2018-11-19       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.